Project Grant R21CA300717
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $700,838 Project Grant to The Regents of the University of California, San Francisco under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 1, 2026 through March 31, 2031. This award supports research and development of an advanced imaging and treatment planning system designed to optimize Stereotactic Body Radiation Therapy (SBRT) for liver cancer patients while minimizing...
- Federal Project Grant Award Summary The University of California, Davis received a $149,394 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective August 1, 2025 through July 31, 2030. This award supports research in targeted radiotheranostics—the development and clinical translation of diagnostic and therapeutic radiopharmaceuticals that enable integrated imaging and treatment of cancer. The research encompasses the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a Project Grant of $679,290 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 1, 2026 through March 31, 2031. The project focuses on translating novel hyperpolarized (HP) carbon-13 dual-agent magnetic resonance imaging (MRI) techniques to improve prostate cancer detection and biopsy guidance. The research aims to develop and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $297,074 Project Grant to the University of California, Davis on August 8, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate Fluorescence Lifetime Imaging (FLIM) technology integrated into standard colonoscopy procedures for enhanced colorectal cancer detection. The project, which extends through July 31, 2030, will deliver three primary products: (1) a comprehensive in...
- Federal Project Grant Award Summary The National Cancer Institute (National Institutes of Health) awarded a $712,375 Project Grant to the University of California, Berkeley under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on April 1, 2026, with a completion date of March 31, 2031. The award funds development of the ADAPT PRO system, a digitally programmable radiofrequency (RF) system designed to enable Magnetic Resonance Imaging (MRI) of any nucleus beyond the standard...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $382,449 Project Grant to the University of California, Los Angeles under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 16, 2025, with completion targeted for June 30, 2027. This research project develops and validates advanced dual-nuclei magnetic resonance imaging (MRI) techniques to non-invasively differentiate between recurrent brain metastases (RBM) and radiation-induced necrosis (RN)...
- Federal Grant Award Summary The National Cancer Institute awarded a $648,049 Project Grant to the University of California, Irvine, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop protoacoustic imaging technology for real-time Bragg peak localization during proton therapy. The award, effective April 2, 2026, through March 31, 2031, will deliver a dual-modality protoacoustic/ultrasound imaging system designed to precisely monitor radiation dose delivery and...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $729,587 on August 21, 2025, to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to develop a personalized voxel-wise prediction model for brain metastases using multi-parametric magnetic resonance imaging. The research deliverable addresses a significant clinical challenge in non-small cell lung cancer adenocarcinoma patients by creating a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $593,557 on March 18, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop magnetic resonance (MR) imaging methods for real-time measurement and control of BPM31510, an emerging lipophilic cancer therapy. The research addresses a critical clinical translation challenge by creating tools to monitor tumor response in real time,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, with a completion date of March 31, 2031. This five-year research initiative focuses on dissecting the role of Carnitine Palmitoyltransferase 1C (CPT1C) in advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC), an aggressive subtype that emerges from...
The National Cancer Institute awarded a $409,141 Project Grant to the University of California, Davis, effective June 1, 2026, through May 31, 2028, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). The grant supports research and development of perfusion computed tomography (CT) imaging technology as an alternative diagnostic tool for liver radioembolization treatment planning. The project aims to validate contrast-enhanced perfusion CT as a replacement for the current complex liver cancer workup procedure, which combines cone-beam CT vascular imaging and single photon emission computed tomography (SPECT) imaging. The anticipated deliverables include a refined imaging methodology capable of mapping liver vasculature, predicting lung shunt fraction—a critical safety parameter for selective internal radiation therapy (SIRT) with yttrium-90 microspheres—and forecasting radiation dose distribution to tumors. The research addresses a significant clinical need to streamline and improve treatment planning for advanced hepatocellular carcinoma patients while reducing procedural burden, cost, and patient risk. By establishing perfusion CT as a validated diagnostic alternative, the project will potentially enable more efficient tumor targeting in radioembolization therapy and support improved clinical outcomes for liver cancer patients. The work is conducted at UC Davis's Davis, California campus and leverages preliminary data from four-phase abdominal CT studies to advance this diagnostic imaging platform.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $409.1k | 4/1/26 |